Wednesday, July 20, 2022

SBIA | TODAY TOO - Office of Study Integrity and Surveillance (OSIS) Workshop 2022: CDER Inspections of Good Laboratory Practice, Animal Rule, and Bioavailability/Bioequivalence Study Sites

Don't forget!
CDER SBIA Webinar Registration

FDA | CDER | Small Business and Industry Assistance

CONFERENCES

Office of Study Integrity and Surveillance Workshop 2022: CDER Inspections of Good Laboratory Practice, Animal Rule, and Bioavailability/Bioequivalence Study Sites

TODAY

July 19 - 20, 2022

Day 1 -  ET

Day 2 -  ET

 

NOTE: Registration and real-time attendance via Adobe Connect is required for continuing education (CE) for physicians, pharmacists, and nurses.  

Real-time attendance is required for the certificate of attendance which can be used in support of CEs for RAPS, SOCRA, ACRP, and SQA.  


Join Live Adobe Connect Webcast (CE and Question Submission)


Registration and Agenda


View Live Broadcast on YouTube (No CE or Question Submission) - Day 2


ABOUT THIS WORKSHOP

This workshop will:

  • Describe the Mission and Vision of the Office of Study Integrity and Surveillance (OSIS)
  • Identify the basic elements needed for a bioanalytical lab to successfully undergo an FDA inspection
  • Provide an overview of compliance programs dealing with inspections of facilities that perform Good Laboratory Practice (GLP), Animal Rule (AR), In Vivo Clinical Bioavailability (BA) -Bioequivalence (BE) , In Vivo Analytical BA/BE
  • Engage attendees to work through case studies representative of the above programs.

TOPICS COVERED

  • Overview of Good Laboratory Practice (GLP), Animal Rule (AR), Compliance Programs (CPs) and inspections
  • Guidance updates – Pathology Peer Review and Whole Slide Imaging
  • OSIS BA/BE Program that includes BA Studies 505(b)2, BE studies, In Vitro BE studies and immunogenicity studies
  • Expectations during BA/BE Inspections – Immunogenicity, Clinical CP, Clinical Endpoints and Analytical Studies
  • Reserve sample requirements
  • Case studies representing the different compliance programs.

FDA RESOURCES


INTENDED AUDIENCE

  • Regulatory affairs professionals who submit INDs, NDAs, BLAs and ANDAs that include bioanalytical study data
  • Regulatory affairs professionals who are involved in GLP-regulated nonclinical laboratory studies and Animal Rule study data
  • Researchers involved in regulated bioanalysis
    Sponsors planning studies involving bioanalysis
  • Industry professionals associated analytical laboratories that involve bioanalysis

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration · 
10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA
GovDelivery logo

No comments:

Post a Comment